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Abstract 
Objectives: The PROSE trial purpose is to investigate whether the incidence of thromboembolic—related complica-
tions is reduced with a current generation mechanical prosthesis (On-X Life Technologies/CryoLife Inc.—On-X) com-
pared with a previous generation mechanical prosthesis (St Jude Medical—SJM). The primary purpose of the initial 
report is to document the preoperative demographics, and the preoperative and operative risk factors by individual 
prosthesis and by Western and Developing populations.
Methods: The PROSE study was conducted in 28 worldwide centres and incorporated 855 subjects randomized 
between 2003 and 2016. The study enrollment was discontinued on August 31, 2016. The preoperative demographics 
incorporated age, gender, functional class, etiology, prosthetic degeneration, primary rhythm, primary valve lesion, 
weight, height, BSA and BMI. The preoperative and operative evaluation incorporated 24 risk factors.
Results: The total patient population (855) incorporated On-X population (462) and the St Jude Medical popula-
tion (393). There was no significant difference of any of the preoperative demographics between the On-X and SJM 
groups. The preoperative and operative risk factors evaluation showed there was no significant difference between 
the On-X and St Jude Medical populations. The preoperative and operative risk factors by valve position (aortic and 
mitral) also documented no differentiation. The dominant preoperative demographics of the Western world popula-
tion were older age, male gender, sinus rhythm, aortic stenosis, congenital aortic lesion, and mitral regurgitation. 
The dominant demographics of the Developing world population were rheumatic etiology, atrial fibrillation, aortic 
regurgitation, mixed aortic lesions, mitral stenosis and mixed mitral lesions. The Developing world group had only one 
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Introduction
The purpose of the PROSE (Prospective Randomized 
Trial of the On-X Mechanical Prosthesis and the St Jude 
Medical Mechanical Prosthesis Evaluation) study is to 
investigate whether the incidence of thromboembolic-
related complications (TRC) is reduced with a current 
generation mechanical prosthesis (On-X Life Tech-
nologies/CryoLife Inc—On-X) compared with a previ-
ous generation mechanical prosthesis (St Jude Medical 
Inc—SJM). The study hypothesis was designed to access 
the null (H0) and alternative (HA) hypotheses.
Methods
The study design of the PROSE trial was a multi-centre, 
randomized trial that would sequentially enrol 400 eli-
gible patients in each group from up to 25 participat-
ing study centres (the actual enrollment centres was 
28 centres) in worldwide centres incorporating West-
ern and Developing countries. The UN Development 
Programme (UNDP) value for the Human Develop-
ment Index (HDI) identified arbitrarily the use of 0.9 
and above for Western developed countries and 0.75 
and below for Developing countries. The categoriza-
tion revealed essentially a 50/50 split in the total study 
population. A country such as China which could be 
considered in the transition expressed no interest in 
participation in the study. To ensure adequate enrol-
ment, the number of mechanical prosthesis implants 
performed was the key criterion in selection of these 
sites. It was estimated that each centre would be able to 
randomize a minimum of 30–40 patients. In actual fact, 
the distribution of the patients per centre did not meet 
this anticipated distribution. The final analysis would 
begin approximately one year after the final patient was 
enrolled, resulting in study completion within five (5) 
years.
The patient eligibility of the trial included the inclusion 
and exclusion criteria. Patient eligibility was determined, 
and patient consent was obtained within seven (7) days 
before operation.
The inclusion criteria were:
1. The patient required an isolated mitral or isolated 
aortic prosthesis replacement. (Patients undergoing 
coronary artery bypass and/or concomitant repair of 
mitral or tricuspid valves were eligible).
2. The patient would be a candidate for receipt of a 
mechanical heart prosthesis.
3. The patient (or legal guardian) had signed a study-
specific informed consent form agreeing to the ran-
domization, data collection and follow-up require-
ments.
4. The patient could be having a re-operative proce-
dure with the previous prosthesis explanted and the 
patient does not become a double prosthesis implan-
tation patient.
The exclusion criteria were:
1. The patient was not a candidate to receive a mechan-
ical heart prosthesis.
2. The patient already had a prosthetic valve other than 
the prosthesis (es) being replaced at the time of the 
study commencement.
3. The patient required a tricuspid replacement.
4. The patient was enrolled in another investigative 
study or trial.
The randomization assignment of patients in the 
PROSE trial eliminated potential selection biases and 
reduced the likelihood of disproportionate distribu-
tion of both known and unknown prognostic fac-
tors between the treatment control groups. The study 
personnel at each site determined the randomization 
assignment during surgery by opening a sequentially 
numbered, sealed envelope for each eligible patient. 
Using this envelope system, patients were randomized 
with equal probability with one or two treatment 
groups, On-X mechanical prosthesis or SJM mechani-
cal prosthesis. The random assignment of patients 
would be different for both aortic and mitral position. 
All study personnel were blinded to the randomization 
schedule. A randomization log containing procedural 
instructions and log sheets for recording randomization 
information were provided to each site. Any violations 
significant risk factor, congestive heart failure. The majority of the preoperative and operative risk factors were signifi-
cant in the Western world population.
Conclusions: The preoperative demographics do not differentiate the prostheses but do differentiate the Western 
and Developing world populations. The preoperative and operative risk factors do not differentiate the prostheses 
BUT do differentiate the Western and Developing world populations.
Keywords: Mechanical prostheses (demographics and risk factors), Experience Western world and Developing world
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of the randomization assignment were communicated 
to the co-ordinating centre following the discovery.
The follow-up of patients occurred at discharge, 
3-months, 6-months, at 1-year and annually thereaf-
ter during the conduct of the study and the longitudi-
nal evaluation to approximately 5-years. Data collected 
included information regarding adverse events as 
defined as the “Guidelines for reporting morbidity and 
mortality after cardiac valvular operations” of the Soci-
ety of Thoracic Surgeons and the American Associa-
tion for Thoracic Surgery (STS/AATS) [1]. The specific 
adverse events of thromboembolism and hemorrhage 
were specifically delineated. The thromboembolic 
events were delineated as reversible ischemic neuro-
logical deficit (RIND), major and thrombosis and were 
confirmed by clinical evaluation, echocardiography 
or computerized scans, as needed. The hemorrhagic 
events were all major events as defined by the guide-
lines inclusive of hospitalization and/or blood product 
transfusion as an in-patient or an outpatient. The addi-
tional follow-up included New York Heart Association 
(NYHA) functional classification, specific procedures 
and medications. The follow-up was initially conducted 
by telephone evaluation and contact with the attend-
ing physician as deemed necessary. If difficulty was 
encountered in obtaining the needed follow-up and/
or complications from the information, the patient 
was contacted and scheduled for an office visit by the 
centre investigator. If this was not possible, the inves-
tigator contacted the patient’s follow-up physician to 
obtain the required data. The patient management 
was conducted by the patient’s attending physician, 
whether that be family physician, internist or cardi-
ologist. The attending physician received notification 
that the patient was involved in the PROSE study along 
with recommendations with regard to target antico-
agulation. The target anti-coagulation level for aortic 
prostheses was INR between 2.2 and 2.8 and mitral 
prostheses was for 2.5–3.5.
The sample size for the PROSE randomized trial was 
dependent upon many assumptions including a pro-
jected rate of events, the measure required to detect the 
difference between the treatment and control groups, 
the selected Type I and Type II error rates and the type 
of significant tests used. The sample size calculation for 
the PROSE study assumed a rate of 1.0% per patient for 
major thrombotic events with the On-X prosthesis and 
a rate of 2.0% per patient for the St Jude Medical pros-
thesis based on existing literature [2–11]. The sample size 
was calculated on the rate of late thromboembolic major 
events that was standardly reported in the literature or 
from regulatory trials for the prostheses.
It was assumed that the treatment group (On-X) would 
experience a 50% reduction in the incidence of major 
thromboembolic events relative to the SJM group. The 
50% magnitude of major thromboembolic event reduc-
tion was considered clinically important, as well as 
detectable with the expected sample size. An exponential 
maximum likelihood test of equality of survival curves 
with a 0.050 one-sided significance level would have 80% 
power to detect the difference between a rate of 0.0100 
for the On-X prosthesis and a rate of 0.0200 for the SJM 
prosthesis.
The data analysis will be performed with an “intent to 
treat” analysis, with no crossovers in the trial, actually 
not allowed in the trial. For the data analysis patients 
will be included in the treatment group in which they 
were assigned. By randomizing patients during surgery, 
deviations from the randomization assignment and the 
resulting of the dilution of the treatment effects would be 
minimized.
Linearized occurrence rates will be utilised to deter-
mine the performance of the prostheses with regard to 
the overall and major thromboembolic events and haem-
orrhage events. Kaplan–Meier analysis will also be uti-
lised to evaluate the performance of the two prostheses 
with regard to freedom from thromboembolic events. A 
log-rank test will be utilised to validate the significance of 
the Kaplan–Meier analysis.
The true significance of the On-X mechanical pros-
thesis in reducing the incidence of thromboembolism 
is unknown. The current documented thromboembolic 
rates with the On-X prosthesis comes from the regula-
tory trials conducted for the Food & Drug Administra-
tion of the United States, and clinical studies [2–6]. The 
thromboembolic rates for the St Jude Medical prosthesis 
are well documented in the literature from publications 
over the past 20  years [7–11]. The thromboembolism 
rate for the On-X prosthesis was considered to be 1.0%/
patient-year from the regulatory trials and that of the 
SJM prosthesis to be 2.0%/patient- year from the exten-
sive publications. Final analysis of the randomized trial 
will be reviewed to ascertain if the observed differences 
are clinically important.
The Adjudication Committee of the PROSE study 
consisted of the Data Safety Monitoring Board (DSMB) 
and the co-ordinating centre for the PROSE study at the 
Vancouver site. The primary end-point adjudication was 
conducted blinded to the DSMB. This method of adju-
dication blinding of end-point events is the only achiev-
able method in a heart valve prosthesis study. The PROSE 
study utilized Case Report Forms for collection of the 
data. Each PI monitored their centre for severe adverse 
events as defined by the STS/AATS guidelines [1]. The 
sponsor and each of the centres reported the serious 
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adverse events (SAE) to the appropriate governments, as 
required by each country’s law for commercially distrib-
uted products.
The PROSE study was carried out according to the 
principals of the Helsinki Declaration. The written, 
informed consent for an eligible patient was required 
before the patient could be included in the investigational 
trial. The signed consent indicated that the patient agreed 
to accept the random assignment of the type of prosthe-
sis, either SJM or On-X. Each of the patients indicated 
that he/she would adhere to the follow-up examination 
schedule and completing annual data collection surveys. 
The signed consent form also included a statement that 
the study data would be made available to the sponsor 
(On-X Life Technologies/CryoLife Inc.). The institu-
tional IRB (University and/or hospital) representing the 
prospective study site reviewed and approved the investi-
gational plan and the prospective investigator’s participa-
tion before the investigation began at the site.
The risks of valve replacement with either of these 
mechanical prostheses are those associated with all pros-
thetic replacement surgery, including thromboembolism 
and bleeding, which are the focus of this study. The out-
come of adverse events typical of prosthesis replacement 
can be transient or permanent and including death. The 
risk of participating in the study was that patients (50% 
of patients) could turn out to receive a prosthesis type 
that was associated with more thromboembolic events 
(blood clots) than the other prosthesis type they could 
have received. The study was designed to determine 
which prosthesis was safer. There was no specific benefit 
to participating in the study. The relative safety of the two 
prosthesis types was unknown at this time, although both 
prostheses are approved for commercial use by Canadian 
and United States governments, and all major worldwide 
governments. The determination of the relative safety 
was the reason for the study.
The patient progress and health status were carefully 
monitored in patients who were involved in the study, 
and any complications that arose were detected and 
treated (if necessary) at an early stage. Knowledge gained 
by participation in the study could be of potential benefit 
to other patients. The assessment of patient information 
gathered in the study would provide information that 
would assist in identifying the optimal heart prosthesis 
type for a patient with varied health and heart histories. 
It was possible that if the clinical results for one of the 
heart prostheses was superior, then the patient receiv-
ing that heart prosthesis could benefit from a reduction 
in the potential complications of mechanical prostheses. 
Any information identified that would be of importance 
to continuing participation will be disclosed in patients 
in a timely fashion. The alternative to participating in this 
study is to have valve replacement with the prosthesis of 
choice selected by the patient and attending cardiologist 
and cardiac surgeon.
Results
The total population for analysis in the PROSE trial was 
855 patients implanted between 2003 and 2016. There 
were 939 patients screened for the trial. Of the trial 
patients—16 discontinued/withdrew and 84 were lost to 
follow-up. The enrollment on the PROSE trial was com-
pleted on August 31, 2016. The follow-up for the PROSE 
trial will complete August 2021.
The preoperative demographics and risk factors for the 
total population is detailed in Tables  1, 2, 3 and 4. The 
preoperative demographics and risk factors by aortic and 
mitral valve positions are detailed in the Additional file 1: 
Tables E1–E4.
The total population (Table 1) of the PROSE study com-
prised 855 patients with On-X population 462 patients 
and the SJM population 393 patients. The Australian sites 
had 84 patients and conducted the randomization 2:1 
On-X to SJM. This issue was corrected by randomization 
in blocked groups of 20 to force a difference of no more 
than 2 in the block which kept further randomization 
equal. The Excel random number generator was utilized 
to create randomization envelopes for the study. Due to 
the 2:1 randomization in Australia, the expected ratio for 
the complete population was 0.48, SJM (i.e., 410 expected 
of 855) to On-X (445 expected) (as noted in the footnote 
to Table 1). The p value with the Australian recruitment 
variance considered for the population was 0.232, indi-
cating satisfactory randomization. Because randomiza-
tion remains within statistical acceptability, this variation 
is not expected to affect results. This anomaly was identi-
fied after the Canadian centers commenced the study.
Table 1 identifies specific differences between the On-X 
and SJM prostheses populations, with a gender difference 
that is also reflected in the lesion distribution and body 
surface area but not individually in height and weight. 
The mean age of the total population was 49.0 years with 
a standard deviation of 12.6  years. The gender distribu-
tion was 58.8% male. Rheumatic valve etiology was 41.6% 
while calcific valvular disease was 29.8%. Sinus rhythm 
was present in 75.2% of patients and atrial fibrillation was 
present in 23.1% of patients.
The preoperative demographics for Aortic Valves (E1) 
and Mitral Valves (E2) revealed significant differences 
similar to the entire population only in the aortic posi-
tion between On-X and SJM prostheses. The mean age 
for aortic prostheses patients was 52.3 +/− 11.4  years. 
Aortic patients were 13.7% rheumatic and 46.9% were 
calcific valvular disease. Of the aortic patients 92.4% 
were in sinus rhythm and only 5.6% were in atrial 
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fibrillation. The mean age for mitral prostheses patients 
was 44.4 +/− 12.8  years. Mitral patients were 81.7% 
rheumatic and 5.0% were calcific valvular disease. Of the 
mitral patients 51.3% were in sinus rhythm and 47.6% 
were in atrial fibrillation.
The preoperative and operative risk factors for the 
total population are detailed in Table 2, while for aortic 
prostheses was detailed in Additional file 1: Table E3 and 
for mitral prostheses was detailed in Additional file  1: 
Table  E4. There were no significant differences between 
On-X and SJM patients for all preoperative and operative 
risk factors.
The Western and Developing Worlds provided the 
most significant differences for both preoperative 
and operative demographics (Table  3) and for pre-
operative and operative risk factors (Table  4). The 
Table 1 Preoperative demographics whole population
p-value considered significant when < 0.05 and highlighted in those cases
*Test for randomization across whole trial includes an adjustment from p = 0.5, because the Australian cohort was randomized 2:1 not 1:1 arriving at p = 0.48 for the 
trial
Factor Whole study On-X SJM p Value
Patients (N) 855 462 393 0.232*
Follow-up (ptyrs) 4078.0 2219.8 1858.3
Age (mean—SD) 49.0–12.6 49.2–12.7 48.9–12.4 0.728
Gender (N—% male) 503–58.8 287–62.1 216–55.0 0.036
NYHA (N—%)
 I 69–8.1 40–8.7 29–7.4 0.091
 II 298–34.8 154–33.3 144–36.6
 III 369–43.2 193–41.8 176–44.8
 IV 78–9.1 45–9.7 33–8.4
 Unknown 41–4.8 30–6.5 11–2.8
Etiology (N—%)
 Rheumatic 344–41.6 183–41.6 161–41.6 0.861
 Calcific 246–29.8 132–30.0 114–29.5
 Prosthetic Degeneration 20– 2.4 13–3.0 7–1.8
 Congenital 109–13.2 54–12.3 55–14.2
 Endocarditis 37–4.5 21–4.8 16–4.1
 Degenerative 56–6.8 30–6.8 26–6.7
 Other 15–1.8 7–1.6 8–2.1
Primary rhythm (N—%)
 Sinus 627–75.2 338–75.1 289–75.3 0.912
 Atrial fibrillation 193–23.1 105–23.3 88–22.9
 Paced 3–0.4 1–0.2 2–0.5
 Other 11–1.3 6–1.3 5–1.3
Aortic lesion (N—%)
 Stenosis 281–56.8 141–52.6 140–61.7 0.0499
 Regurgitation 82–16.6 42–15.7 40–17.6
 Mixed 130–26.3 84–31.3 46–20.3
 Other 2–0.4 1–0.4 1–0.4
Mitral lesion (N—%)
 Stenosis 80–23.2 49–26.5 31–19.4 0.224
 Regurgitation 68–19.7 35–18.9 33–20.6
 Mixed 195–56.5 99–53.5 96–60.0
 Other 2–0.6 2–1.1 0–0.0
Weight in kg (mean—SD) 73.2–22.1 74.2–22.5 72.0–21.6 0.147
Height in cm (mean—SD) 166.5–11.2 167.2–11.2 165.7–11.1 0.0504
Body surface area in  m2 (mean—SD) 1.80–0.29 1.82–0.29 1.78–0.28 0.042
Body mass index in kg/m2 (mean—SD) 26.2–7.0 26.3–7.2 26.0–6.7 0.531
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preoperative demographics revealed the patients in the 
Developing world were younger (43.3 +/− 12.6 years ver-
sus 54.5 +/− 9.8 < 0.0001), predominantly female (54.0% 
versus 29.0% < 0.0001), predominantly rheumatic disease 
(70.1% vs. 7.9% < 0.0001), and in atrial fibrillation (35.6% 
vs. 10.1% < 0.0001).
Aortic stenosis was more common in the Western 
world (66.5% vs. 26.1% < 0.0001) while aortic regurgi-
tation more common in the Developing world (27.7% 
vs. 13.0% < 0.0001) (Table  3). Mixed mitral disease was 
more common in the Developing world (60.7% vs. 
32.0% < 0.0001) while mitral regurgitation was more com-
mon in the Western world (42.0% vs. 15.9% < 0.0001) 
(Table 4).
The preoperative and operative risk factors for West-
ern and Developing worlds (Table 4) revealed a complete 
contrast for almost all risk factors with the significant 
factors predominantly in the Western world. The com-
parative risk factors that had higher occurrence rates 
or measured values in the Western world population 
were—coronary artery disease (29.1% vs. 4.3% < 0.0001), 
diabetes mellitus (15.1% vs. 7.7% 0.0004), hypercholes-
terolemia (44.2% vs. 6.7% < 0.0001), preoperative creati-
nine (98.1 +/− 91.0  µmol/L vs. 82.9 +/− 28.5  µmol/L, 
p = 0.001), hypertension (55.6% vs. 20.6% < 0.0001), 
COPD (14.0% vs. 4.8% < 0.0001), previous myocardial 
infarction (8.2% vs. 1.2% < 0.0001), angina pectoris (20.6% 
vs. 6.2% < 0.0001). The aortic valve percentage was more 
common in the Western world (87.2% vs. 29.0% < 0.0001). 
Intraoperative adverse events were more common in 
the Western world (12.8% vs. 4.8% < 0.0001). Congestive 
heart failure, on the other hand, was more common in 
the Developing world (29.3% vs. 21.7% 0.011).
Discussion
Table 5 (Figs. 1 and 2).
On-X specific design features (Table 5, Fig. 1)
As compared in Table  5 the On-X prosthesis is a pure 
pyrolytic carbon prosthesis with a supraannular sewing 
ring. The prosthesis design facilitates pannus protection 
(pannus protection was not a comparative feature of the 
Table 2 Preoperative and operative risk factors whole study
Factor Whole study On-X SJM p Value
Smoker (N—%) 303–35.4 171–37.0 132–33.6 0.301
Coronary disease in family (N—%) 145–17.0 79–17.1 66–16.8 0.907
Diabetes (N—%) 98–11.5 52–11.3 46–11.7 0.855
High cholesterol (N— %) 221–25.8 130–28.1 91–23.2 0.103
Preoperative creatinine (mean—SD) 89.8–65.1 91.7–71.6 87.6–56.8 0.360
Renal failure (N—%) 35–4.1 18–3.9 17–4.3 0.768
Hypertension (N—%) 329–38.5 176–38.1 153–38.9 0.811
History of CVA (N—%) 45–5.3 26–5.6 19–4.8 0.601
Previous endocarditis (N—%) 37–4.3 23–5.0 14–3.6 0.318
Existing COPD (N—%) 81–9.5 45–9.7 36–9.2 0.804
Immunosuppressed (N—%) 12–1.4 8–1.7 4–1.0 0.382
Peripheral vascular disease (N—%) 23–2.7 16–3.5 7–1.8 0.128
Carotid vascular disease (N—%) 45–5.3 23–5.0 22–5.6 0.696
Previous cardiac surgery (N—%) 124–14.5 66–14.3 58–14.8 0.836
Previous MI (N— %) 41–4.8 24–5.2 17–4.3 0.539
Congestive heart failure (N—%) 217–25.4 124–26.8 93–23.7 0.300
Angina (N—%) 116–13.6 60–13.0 56–14.2 0.610
Cardiogenic shock (n—%) 4–0.5 3–0.6 1–0.3 0.519
Resuscitation (N—%) 5–0.6 3–0.6 2–0.5 0.844
Ejection fraction % (mean—SD) 55.5–11.5 55.2–11.4 55.9–11.5 0.373
Preoperative status (N—%)
 Elective 657–84.0 355–84.9 302–83.0 0.757
 Urgent 119–15.2 60–14.4 59–16.2
 Emergent 6–0.8 3–0.6 3–0.8
Aortic valve percentage 502–58.7 273–59.1 229–58.2
Concomitant procedures (N—%) 286–33.4 152–32.9 134–34.1 0.711
Intraoperative AE’s (N—%) 76–8.9 42–9.1 34–8.7 0.838
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PROSE trial). The long, flared orifice of the On-X pros-
thesis facilitates organized flow through the prosthesis 
(height-to-diameter ratio of about 0.6). The actuated piv-
ots of the On-X prosthesis allow the leaflets to follow the 
blood flow through the prosthesis. The pivot purge of the 
On-X prosthesis facilitates the elimination of blood sta-
sis in the prosthesis. The two-point closure of the On-X 
reduces the impact of leaflet closure.
SJM specific design features (Table 5, Fig. 2)
The SJM prosthesis is made from a silicon-alloyed pyro-
lytic carbon that is less strong and more brittle than 
pure pyrolytic carbon. It also features a supra-annular 
sewing ring, but its orifice does not extend above and 
below the ring except at the pivot ears providing little 
barrier to pannus overgrowth. The height-to-diameter 
ratio of the housing is approximately 0.3. Its leaflets 
rotate on a fixed pivot and its closing contact points are 
Table 3 Preoperative demographics for Western versus Developing worlds
Factor Whole study Western Developing p Value
Patients (N) 855 437 418
Follow-up (ptyrs) 4078.0 2213.3 1864.8
Age (mean—SD) 49.0–12.6 54.5–9.8 43.3–12.6  < 0.0001
Gender (N—% male) 503–58.8 311–71.2 192–45.9  < 0.0001
NYHA (N—%)
 I 69–8.1 64–14.6 5–1.2  < 0.0001
 II 298–34.8 154–35.2 144–34.4
 III 369–43.2 152–34.8 217–51.9
 IV 78–9.1 48–11.0 30–7.2
 Unknown 41–4.8 19–4.4 22–5.3
Etiology (N—%)
 Rheumatic 344–41.6 30–7.9 314–70.1  < 0.0001
 Calcific 246–29.8 194–51.2 52–11.6
 Prosthetic degeneration 20–2.4 6–1.6 14–3.1
 Congenital 109–13.2 92–24.3 17–3.8
 Endocarditis 37–4.5 16–4.2 21–4.7
 Degenerative 56–6.8 35–9.2 21–4.7
 Other 15–1.8 6–1.6 9–2.0
Primary rhythm (N—%)
 Sinus 627–75.2 364–87.5 263–62.9  < 0.0001
 Atrial fibrillation 193–23.1 44–10.6 149–35.6
 Paced 3–0.4 1–0.2 2–4.8
 Other 11–1.3 7–1.7 4–9.6
Aortic lesion (N—%)
 Stenosis 281–56.8 250–66.5 31–26.1  < 0.0001
 Regurgitation 82–16.6 49–13.0 33–27.7
 Mixed 130–26.3 77–20.5 53–44.5
 Other 2–0.4 0–0.0 2–1.7
Mitral lesion (N—%)
 Stenosis 80–23.2 13–26.0 67–22.7  < 0.0001
 Regurgitation 68–19.7 21–42.0 47–15.9
 Mixed 195–56.5 16–32.0 179–60.7
 Other 2–0.6 0–0.0 2–0.7
Weight in kg (mean—SD) 73.2–22.1 86.0–19.8 60.4–16.1  < 0.0001
Height in cm (mean—SD) 166.5–11.2 172.1–9.7 161.0–9.7  < 0.0001
Body surface area in  m2 (mean—SD) 1.80–0.29 1.98–0.23 1.62–0.21  < 0.0001
Body mass index in kg/m2 (mean—SD) 26.2–7.0 29.1–6.6 23.3–6.1  < 0.0001
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at the tips of the leaflets resulting in a higher likelihood 
of cavitation.
Limitations
The study was designed to approximate standard care 
outside of a trial. As such, elements were left uncontrolled 
and unevaluated, such as routine INR management, even 
though targets were provided. This will cause results 
analysis will be limited appropriately. Further research 
needs may arise from the final analyses.
Table 4 Preoperative and operative risk factors for Western versus Developing worlds
p-value considered significant when < 0.05 and highlighted in those cases
Factor Whole study Western Developing p Value
Smoker (N—%) 303–35.4 231–52.9 72–17.2  < 0.0001
Coronary disease in family (N—%) 145–17.0 127–29.1 18–4.3  < 0.0001
Diabetes (N—%) 98–11.5 66–15.1 32–7.7 0.0004
High cholesterol (N—%) 221–25.8 193–44.2 28–6.7  < 0.0001
Preoperative creatinine (mean—SD) 89.8–65.1 98.1–91.0 83.1–28.4 0.001
Renal failure (N—%) 35–4.1 19–4.3 16–3.8 0.711
Hypertension (N—%) 329–38.5 243–55.6 86–20.6  < 0.0001
History of CVA (N—%) 45–5.3 24–5.5 21–5.0 0.743
Previous endocarditis (N—%) 37–4.3 19–4.3 18–4.3 0.989
Existing COPD (N—%) 81–9.5 61–14.0 20–4.8  < 0.0001
Immunosuppressed (N—%) 12–1.4 11–2.5 1–0.2 0.003
Peripheral vascular disease (N—%) 23–2.7 18–4.1 5–1.2 0.009
Carotid vascular disease (N—%) 45–5.3 26–5.9 19–4.6 0.395
Previous cardiac surgery (N—%) 124–14.5 54–12.4 71–17.0 0.057
Previous MI (N—%) 41–4.8 36–8.2 5–1.2  < 0.0001
Congestive heart failure (N—%) 217–25.4 95–21.7 122–29.3 0.011
Angina (N—%) 116–13.6 90–20.6 26–6.2  < 0.0001
Cardiogenic shock (n—%) 4–0.5 1–0.2 3–0.7 0.272
Resuscitation (N—%) 5–0.6 2–0.5 3–0.7 0.705
Ejection fraction % (mean—SD) 55.5–11.5 56.3–12.9 54.9–10.2 0.080
Preoperative Status (N—%)
Elective 657–84.0 321–88.2 336–80.4 0.023
Urgent 119–15.2 40–11.0 79–18.9
Emergent 6–0.8 3–0.8 3–0.7
Aortic valve percentage 502–58.7 381–87.2 121–29.0  < 0.0001
Concomitant procedures (N—%) 286–33.4 133–30.4 153–36.7 0.051
Intraoperative AE’s (N—%) 76–8.9 56–12.8 20–4.8  < 0.0001
Table 5 On-X versus SJM design comparison
Feature On-X Valve (On-X Fig. 1) SJM Valve (SJM Fig. 2)
Material Pure pyrolytic carbon Silicon-alloyed pyrolytic carbon
Sewing ring position Supra-annular Supra-annular
Valve position Intra-supra-annular Supra-annular
Pannus overgrowth protection Yes No
Orifice length Longer natural length-to-diameter ratio Shorter less than natural 
length-to-diameter ratio
Pivot design Actuated by remote center of rotation Fixed rotation point
Leakage path Smooth through contoured pivot with set gap tolerances Jet through angular pivot
Closing geometry Two points at 45° from leaflet tip reducing closing velocity Single point at tip of leaflet
Page 9 of 10Jamieson et al. J Cardiothorac Surg          (2021) 16:323  
Conclusion
The completion of the long-term follow-up in eight [8] 
residual centres in the Developing world will provide the 
opportunity to evaluate the influence of prosthesis-type 
on major thromboembolism, thrombosis and major hem-
orrhage in accordance with the objectives of the PROSE 
trial. The influence of prosthesis-type in the Western 
world and the Developing world will also be evaluated for 
major thromboembolism, thrombosis and hemorrhage. 
These comparisons will be conducted by the overall pop-
ulation and by valve position. The PROSE study findings 
will afford the opportunity for comparison to the existing 
world literature.
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